awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q40398050-2965086A-DC6B-4BAF-9EC6-77F03049CFB5
Q40398050-2965086A-DC6B-4BAF-9EC6-77F03049CFB5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40398050-2965086A-DC6B-4BAF-9EC6-77F03049CFB5
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
P2860
Q40398050-2965086A-DC6B-4BAF-9EC6-77F03049CFB5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40398050-2965086A-DC6B-4BAF-9EC6-77F03049CFB5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8cb63a120816e469ee1d80935b8014c66a12675f
P2860
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).